Načítá se...

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations

The introduction in clinical practice of pharmaceutical products known as biosimilars, as part of a more complex series of progress in the field of biological drugs, represents an excellent therapeutic resource. A biosimilar drug is a biological/biotechnological drug that is highly similar to an app...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Ther
Hlavní autoři: Francescon, Sara, Fornasier, Giulia, Baldo, Paolo
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2016
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315076/
https://ncbi.nlm.nih.gov/pubmed/28261647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0028-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!